
Colleen F Hanrahan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4571223/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Conditional Cash Transfers to Incentivize Tuberculosis Screening: Description of a Novel Strategy for Contact Investigation in Rural South Africa. Clinical Infectious Diseases, 2022, 74, 957-964.	5.8	1
2	Curating the Evidence About COVID-19 for Frontline Public Health and Clinical Care: The Novel Coronavirus Research Compendium. Public Health Reports, 2022, 137, 197-202.	2.5	2
3	Novel health system strategies for tuberculin skin testing at primary care clinics: Performance assessment and health economic evaluation. PLoS ONE, 2021, 16, e0246523.	2.5	Ο
4	High conversion of tuberculin skin tests during the first year of antiretroviral treatment among South African adults in primary care. Aids, 2021, 35, 1775-1784.	2.2	2
5	Association between monocyte-to-lymphocyte ratio and tuberculin skin test positivity in HIV-positive adults. PLoS ONE, 2021, 16, e0253907.	2.5	5
6	Perceptions of Community and Clinic-Based Adherence Clubs for Patients Stable on Antiretroviral Treatment: A Mixed Methods Study. AIDS and Behavior, 2020, 24, 1197-1206.	2.7	17
7	Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics. AIDS and Behavior, 2020, 24, 1106-1117.	2.7	7
8	A clinical score for identifying active tuberculosis while awaiting microbiological results: Development and validation of a multivariable prediction model in sub-Saharan Africa. PLoS Medicine, 2020, 17, e1003420.	8.4	13
9	Brief Report: Proportion and Predictors of Adult TB Contacts Accepting HIV Testing During an Active TB Case Finding Intervention in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 525-529.	2.1	Ο
10	Title is missing!. , 2020, 17, e1003420.		0
11	Title is missing!. , 2020, 17, e1003420.		0
12	Title is missing!. , 2020, 17, e1003420.		0
13	Title is missing!. , 2020, 17, e1003420.		Ο
14	Title is missing!. , 2020, 17, e1003420.		0
15	The impact of community- versus clinic-based adherence clubs on loss from care and viral suppression for antiretroviral therapy patients: Findings from a pragmatic randomized controlled trial in South Africa. PLoS Medicine, 2019, 16, e1002808.	8.4	28
16	Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB). PLoS Medicine, 2019, 16, e1002796.	8.4	36
17	Health system barriers to implementation of TB preventive strategies in South African primary care facilities. PLoS ONE, 2019, 14, e0212035.	2.5	22
18	From Epidemiologic Knowledge to Improved Health: A Vision for Translational Epidemiology. American Journal of Epidemiology, 2019, 188, 2049-2060.	3.4	10

2

Colleen F Hanrahan

#	Article	IF	CITATIONS
19	Diagnostic strategies for childhood tuberculosis in the context of primary care in a high burden setting: the value of alternative sampling methods. Paediatrics and International Child Health, 2019, 39, 88-94.	1.0	9
20	Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment. AIDS and Behavior, 2019, 23, 1689-1697.	2.7	8
21	Mental health in South African adolescents living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 117-124.	1.2	27
22	The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1298-1305.	1.2	5
23	Maternal priorities for preventive therapy among <scp>HIV</scp> â€positive pregnant women before and after delivery in South Africa: aÂbest‑'worst scaling survey. Journal of the International AIDS Society, 2018, 21, e25143.	3.0	11
24	Chest X-ray for tuberculosis preventive therapy: use caution. Lancet HIV,the, 2018, 5, e478-e479.	4.7	2
25	Improving active case finding for tuberculosis in South Africa: informing innovative implementation approaches in the context of the Kharitode trial through formative research. Health Research Policy and Systems, 2017, 15, 42.	2.8	22
26	A proposed novel framework for monitoring and evaluation of the cascade of HIVâ€associated TB care at the health facility level. Journal of the International AIDS Society, 2017, 20, 21375.	3.0	5
27	Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infectious Diseases, 2016, 16, 661.	2.9	34
28	Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infectious Diseases, 2016, 3, ofw068.	0.9	42
29	Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. The Cochrane Library, 2016, , CD011420.	2.8	111
30	Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis. American Journal of Epidemiology, 2016, 183, 407-414.	3.4	9
31	Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Scientific Reports, 2015, 4, 5658.	3.3	100
32	The patient impact of point-of-care vs. laboratory placement of Xpert [®] MTB/RIF. International Journal of Tuberculosis and Lung Disease, 2015, 19, 811-816.	1.2	31
33	High Uptake of Systematic HIV Counseling and Testing and TB Symptom Screening at a Primary Care Clinic in South Africa. PLoS ONE, 2014, 9, e105428.	2.5	9
34	Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States. Clinical Infectious Diseases, 2014, 59, 186-192.	5.8	55
35	Impact of systematic <scp>HIV</scp> testing on case finding and retention in care at a primary care clinic in <scp>S</scp> outh <scp>A</scp> frica. Tropical Medicine and International Health, 2014, 19, 1411-1419.	2.3	9
36	Economic challenges associated with tuberculosis diagnostic development. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 499-510.	1.4	4

#	Article	IF	CITATIONS
37	Xpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1426-1434.	5.6	64
38	Active case finding for tuberculosis: what is the most informative measure for policy makers? [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 377-377.	1.2	5
39	Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. International Journal of Tuberculosis and Lung Disease, 2013, 17, 368-372.	1.2	32
40	Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa. PLoS ONE, 2013, 8, e65421.	2.5	76
41	Verification Bias in a Diagnostic Accuracy Study of Symptom Screening for Tuberculosis in HIV-Infected Pregnant Women. Clinical Infectious Diseases, 2012, 54, 1377-1378.	5.8	5
42	Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 826.	9.1	4
43	The Impact of Expanded Testing for Multidrug Resistant Tuberculosis Using Geontype MTBDRplus in South Africa: An Observational Cohort Study. PLoS ONE, 2012, 7, e49898.	2.5	28
44	Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5353-5357.	2.2	58
45	Body mass index and risk of tuberculosis and death. Aids, 2010, 24, 1501-1508.	2.2	112
46	Discovery of dipiperidines as new antitubercular agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 201-205.	2.2	37
47	Identification of New Diamine Scaffolds with Activity againstMycobacterium tuberculosis. Journal of Medicinal Chemistry, 2006, 49, 3045-3048.	6.4	104
48	Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. British Journal of Pharmacology, 2005, 144, 80-87.	5.4	210
49	Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. Journal of Antimicrobial Chemotherapy, 2005, 56, 968-974.	3.0	338